NCT01451580UnknownPhase 2
A Phase II Study of Pegylated Liposomal Doxorubicin (Lipo-Dox) Combined With Cyclophosphamide /5-Fluorouracil as Second Line Chemotherapy in the Treatment of Metastatic Breast Cancer
TTY Biopharm1 site in 1 country47 target enrollmentStarted: September 1, 2005Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Sponsor
- Enrollment
- 47
- Locations
- 1
Study Overview
Brief Summary
To determine the overall objective response rate of pegylated liposomal doxorubicin (Lipo-Dox)combined with cyclophosphamide/5-FU as second-line treatment in patients with metastatic breast cancer.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Single Group
- Masking
- None
Eligibility Criteria
- Ages
- 20 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •histologically proved breast cancer with metastatic disease
Exclusion Criteria
- •life expectancy less than 3 months.
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Unknown
Phase 2
Pegylated Liposomal Doxorubicin and Carboplatin as First Line Treatment for Patients With Advanced Non-small Cell Lung CancerNon-small Cell Lung CancerNCT01051362The First Affiliated Hospital of Guangzhou Medical University48
Active, not recruiting
Not Applicable
Phase II study of pegylated liposomal doxorubicin (Caelyxâ) in breast cancer patients with brain metastases and not candidate for an antiHER2 therapy - AROBASEBreast Cancer Patients with Brain MetastasesMedDRA version: 9.1Level: PTClassification code 10055113Term: Breast cancer metastaticMedDRA version: 9.1Level: LLTClassification code 10027475Term: Metastatic breast cancerEUCTR2007-006790-81-FRAPREC50
Unknown
Phase 2
Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple MyelomaMultiple Myeloma and Plasma Cell NeoplasmNCT00742404Oncotherapeutics35
Active, not recruiting
Not Applicable
Phase II Study Evaluating PegLiposomal Doxorubicin (PLD) and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal TumorsGynecologic Sarcomas and Mixed Epithelial-Mesenchymal TumorsEUCTR2008-000245-55-DEGYN Research GmbH
Recruiting
Phase 2
A Phase II Trial of Liposomal Doxorubicin (PLD, DOXILTM) as 3rd Line Treatment in Relapsed, Plutinum - resistant Ovarian CancerOvarian CancerJPRN-UMIN000002814Osaka University Faculty of Medicine Department of obstetrics and gynecology43
